Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02998047 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma
A Phase 1 study, sponsored by Actinium Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT02998047: Clinical Trial Phase 1 study, sponsored by Actinium Pharmaceuticals.
NCT02998047 is a Phase 1 study that was terminated before completion, run by Actinium Pharmaceuticals. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02998047, a Phase 1 study, was terminated before completion, sponsored by Actinium Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
1. Establish the MTD of Lintuzumab-Ac225 as monotherapy 2. Establish overall response rate (ORR) where ORR = CR + sCR+ VGPR+PR) 3. Confirm the safety profile of the treatment regimen 4. Estimate progression-free survival (PFS) and overall survival
Primary Outcome
establish the maximum tolerated dose as monotherapy
Interventions
- DRUG Lintuzumab AC 225
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2016-12 |
| Est. Completion | 2020-05 |
| Phase | Phase 1 |
Why NCT02998047 stopped before completion
NCT02998047 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Lintuzumab AC 225 is the first listed.
NCT02998047 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02998047 about?
NCT02998047 is a clinical study titled "A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma". 1. Establish the MTD of Lintuzumab-Ac225 as monotherapy 2. Establish overall response rate (ORR) where ORR = CR + sCR+ VGPR+PR) 3. Confirm the safety profile of the treatment regimen 4. Estimate progression-free survival (PFS) and overall survival
What is the current status of trial NCT02998047?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2016-12. Estimated completion is 2020-05.
What interventions are being tested in trial NCT02998047?
The interventions under investigation include: Lintuzumab AC 225 (DRUG).
Who is sponsoring clinical trial NCT02998047?
This trial is sponsored by Actinium Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02998047's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia